Global Immuno-oncology Drugs Supply, Demand and Key Producers, 2023-2029

Description

The global Immuno-oncology Drugs market size is expected to reach $ 50980 million by 2029, rising at a market growth of 16.0% CAGR during the forecast period (2023-2029).

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Immunotherapy is treatment that uses a certain part of a person’s immune system to fight diseases which is done by stimulating one’s own immune system to work harder to attack cancer cells or by giving immune system components, such as man-made immune system proteins. Immunotherapy includes treatments that work in different ways. Some boost the body’s immune system in a very general way and others help train the immune system to attack cancer cells specifically.

This report studies the global Immuno-oncology Drugs demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Immuno-oncology Drugs, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Immuno-oncology Drugs that contribute to its increasing demand across many markets.

Highlights and key features of the study
Global Immuno-oncology Drugs total market, 2018-2029, (USD Million)
Global Immuno-oncology Drugs total market by region & country, CAGR, 2018-2029, (USD Million)
U.S. VS China: Immuno-oncology Drugs total market, key domestic companies and share, (USD Million)
Global Immuno-oncology Drugs revenue by player and market share 2018-2023, (USD Million)
Global Immuno-oncology Drugs total market by Type, CAGR, 2018-2029, (USD Million)
Global Immuno-oncology Drugs total market by Application, CAGR, 2018-2029, (USD Million).

This reports profiles major players in the global Immuno-oncology Drugs market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Amgen, Inc, AstraZeneca, Plc, Bristol-Myers Squibb, Celgene Corporation, Eli Lilly and Company, Merck & Co., Hoffmann-La Roche AG, Johnson & Johnson and Novartis International AG, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Immuno-oncology Drugs market.

Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global Immuno-oncology Drugs Market, By Region:
    United States
    China
    Europe
    Japan
    South Korea
    ASEAN
    India
    Rest of World

Global Immuno-oncology Drugs Market, Segmentation by Type
    Immune Checkpoint Inhibitors
    Immune System Modulators
    Cancer Vaccines
    Oncolytic Virus
    Others

Global Immuno-oncology Drugs Market, Segmentation by Application
    Hospitals
    Clinics
    Ambulatory Surgical Centers

Companies Profiled:
    Amgen, Inc
    AstraZeneca, Plc
    Bristol-Myers Squibb
    Celgene Corporation
    Eli Lilly and Company
    Merck & Co.
    Hoffmann-La Roche AG
    Johnson & Johnson
    Novartis International AG
    AbbVie, Inc.
    Pfizer Inc.
    Sanofi S.A.
    EMD Serono, Inc.
    Gilead Sciences Inc.
    Prometheus Therapeutics & Diagnostics
    Aduro BioTech
    Galena Biopharma
    Bavarian Nordic
    Celldex Therapeutics
    ImmunoCellular Therapeutics
    Incyte
    Dendreon Corporation
    Agilent Technologies Inc.
    Agenus Inc.
    Enzo Biochem, Inc.
    Lonza Group
    Bio-Rad Laboratories, Inc.
    Avantor, Inc.
    Spring Bank Pharmaceuticals, Inc.
    Ferring Pharmaceuticals

Key Questions Answered
1. How big is the global Immuno-oncology Drugs market?
2. What is the demand of the global Immuno-oncology Drugs market?
3. What is the year over year growth of the global Immuno-oncology Drugs market?
4. What is the total value of the global Immuno-oncology Drugs market?
5. Who are the major players in the global Immuno-oncology Drugs market?

Table of Contents

1 Supply Summary
    1.1 Immuno-oncology Drugs Introduction
    1.2 World Immuno-oncology Drugs Market Size & Forecast (2018 & 2022 & 2029)
    1.3 World Immuno-oncology Drugs Total Market by Region (by Headquarter Location)
        1.3.1 World Immuno-oncology Drugs Market Size by Region (2018-2029), (by Headquarter Location)
        1.3.2 United States Immuno-oncology Drugs Market Size (2018-2029)
        1.3.3 China Immuno-oncology Drugs Market Size (2018-2029)
        1.3.4 Europe Immuno-oncology Drugs Market Size (2018-2029)
        1.3.5 Japan Immuno-oncology Drugs Market Size (2018-2029)
        1.3.6 South Korea Immuno-oncology Drugs Market Size (2018-2029)
        1.3.7 ASEAN Immuno-oncology Drugs Market Size (2018-2029)
        1.3.8 India Immuno-oncology Drugs Market Size (2018-2029)
    1.4 Market Drivers, Restraints and Trends
        1.4.1 Immuno-oncology Drugs Market Drivers
        1.4.2 Factors Affecting Demand
        1.4.3 Immuno-oncology Drugs Major Market Trends

2 Demand Summary
    2.1 World Immuno-oncology Drugs Consumption Value (2018-2029)
    2.2 World Immuno-oncology Drugs Consumption Value by Region
        2.2.1 World Immuno-oncology Drugs Consumption Value by Region (2018-2023)
        2.2.2 World Immuno-oncology Drugs Consumption Value Forecast by Region (2024-2029)
    2.3 United States Immuno-oncology Drugs Consumption Value (2018-2029)
    2.4 China Immuno-oncology Drugs Consumption Value (2018-2029)
    2.5 Europe Immuno-oncology Drugs Consumption Value (2018-2029)
    2.6 Japan Immuno-oncology Drugs Consumption Value (2018-2029)
    2.7 South Korea Immuno-oncology Drugs Consumption Value (2018-2029)
    2.8 ASEAN Immuno-oncology Drugs Consumption Value (2018-2029)
    2.9 India Immuno-oncology Drugs Consumption Value (2018-2029)

3 World Immuno-oncology Drugs Companies Competitive Analysis
    3.1 World Immuno-oncology Drugs Revenue by Player (2018-2023)
    3.2 Industry Rank and Concentration Rate (CR)
        3.2.1 Global Immuno-oncology Drugs Industry Rank of Major Players
        3.2.2 Global Concentration Ratios (CR4) for Immuno-oncology Drugs in 2022
        3.2.3 Global Concentration Ratios (CR8) for Immuno-oncology Drugs in 2022
    3.3 Immuno-oncology Drugs Company Evaluation Quadrant
    3.4 Immuno-oncology Drugs Market: Overall Company Footprint Analysis
        3.4.1 Immuno-oncology Drugs Market: Region Footprint
        3.4.2 Immuno-oncology Drugs Market: Company Product Type Footprint
        3.4.3 Immuno-oncology Drugs Market: Company Product Application Footprint
    3.5 Competitive Environment
        3.5.1 Historical Structure of the Industry
        3.5.2 Barriers of Market Entry
        3.5.3 Factors of Competition
    3.6 Mergers, Acquisitions Activity

4 United States VS China VS Rest of the World (by Headquarter Location)
    4.1 United States VS China: Immuno-oncology Drugs Revenue Comparison (by Headquarter Location)
        4.1.1 United States VS China: Immuno-oncology Drugs Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
        4.1.2 United States VS China: Immuno-oncology Drugs Revenue Market Share Comparison (2018 & 2022 & 2029)
    4.2 United States Based Companies VS China Based Companies: Immuno-oncology Drugs Consumption Value Comparison
        4.2.1 United States VS China: Immuno-oncology Drugs Consumption Value Comparison (2018 & 2022 & 2029)
        4.2.2 United States VS China: Immuno-oncology Drugs Consumption Value Market Share Comparison (2018 & 2022 & 2029)
    4.3 United States Based Immuno-oncology Drugs Companies and Market Share, 2018-2023
        4.3.1 United States Based Immuno-oncology Drugs Companies, Headquarters (States, Country)
        4.3.2 United States Based Companies Immuno-oncology Drugs Revenue, (2018-2023)
    4.4 China Based Companies Immuno-oncology Drugs Revenue and Market Share, 2018-2023
        4.4.1 China Based Immuno-oncology Drugs Companies, Company Headquarters (Province, Country)
        4.4.2 China Based Companies Immuno-oncology Drugs Revenue, (2018-2023)
    4.5 Rest of World Based Immuno-oncology Drugs Companies and Market Share, 2018-2023
        4.5.1 Rest of World Based Immuno-oncology Drugs Companies, Headquarters (States, Country)
        4.5.2 Rest of World Based Companies Immuno-oncology Drugs Revenue, (2018-2023)

5 Market Analysis by Type
    5.1 World Immuno-oncology Drugs Market Size Overview by Type: 2018 VS 2022 VS 2029
    5.2 Segment Introduction by Type
        5.2.1 Immune Checkpoint Inhibitors
        5.2.2 Immune System Modulators
        5.2.3 Cancer Vaccines
        5.2.4 Oncolytic Virus
        5.2.5 Others
    5.3 Market Segment by Type
        5.3.1 World Immuno-oncology Drugs Market Size by Type (2018-2023)
        5.3.2 World Immuno-oncology Drugs Market Size by Type (2024-2029)
        5.3.3 World Immuno-oncology Drugs Market Size Market Share by Type (2018-2029)

6 Market Analysis by Application
    6.1 World Immuno-oncology Drugs Market Size Overview by Application: 2018 VS 2022 VS 2029
    6.2 Segment Introduction by Application
        6.2.1 Hospitals
        6.2.2 Clinics
        6.2.3 Ambulatory Surgical Centers
    6.3 Market Segment by Application
        6.3.1 World Immuno-oncology Drugs Market Size by Application (2018-2023)
        6.3.2 World Immuno-oncology Drugs Market Size by Application (2024-2029)
        6.3.3 World Immuno-oncology Drugs Market Size by Application (2018-2029)

7 Company Profiles
    7.1 Amgen, Inc
        7.1.1 Amgen, Inc Details
        7.1.2 Amgen, Inc Major Business
        7.1.3 Amgen, Inc Immuno-oncology Drugs Product and Services
        7.1.4 Amgen, Inc Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023)
        7.1.5 Amgen, Inc Recent Developments/Updates
        7.1.6 Amgen, Inc Competitive Strengths & Weaknesses
    7.2 AstraZeneca, Plc
        7.2.1 AstraZeneca, Plc Details
        7.2.2 AstraZeneca, Plc Major Business
        7.2.3 AstraZeneca, Plc Immuno-oncology Drugs Product and Services
        7.2.4 AstraZeneca, Plc Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023)
        7.2.5 AstraZeneca, Plc Recent Developments/Updates
        7.2.6 AstraZeneca, Plc Competitive Strengths & Weaknesses
    7.3 Bristol-Myers Squibb
        7.3.1 Bristol-Myers Squibb Details
        7.3.2 Bristol-Myers Squibb Major Business
        7.3.3 Bristol-Myers Squibb Immuno-oncology Drugs Product and Services
        7.3.4 Bristol-Myers Squibb Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023)
        7.3.5 Bristol-Myers Squibb Recent Developments/Updates
        7.3.6 Bristol-Myers Squibb Competitive Strengths & Weaknesses
    7.4 Celgene Corporation
        7.4.1 Celgene Corporation Details
        7.4.2 Celgene Corporation Major Business
        7.4.3 Celgene Corporation Immuno-oncology Drugs Product and Services
        7.4.4 Celgene Corporation Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023)
        7.4.5 Celgene Corporation Recent Developments/Updates
        7.4.6 Celgene Corporation Competitive Strengths & Weaknesses
    7.5 Eli Lilly and Company
        7.5.1 Eli Lilly and Company Details
        7.5.2 Eli Lilly and Company Major Business
        7.5.3 Eli Lilly and Company Immuno-oncology Drugs Product and Services
        7.5.4 Eli Lilly and Company Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023)
        7.5.5 Eli Lilly and Company Recent Developments/Updates
        7.5.6 Eli Lilly and Company Competitive Strengths & Weaknesses
    7.6 Merck & Co.
        7.6.1 Merck & Co. Details
        7.6.2 Merck & Co. Major Business
        7.6.3 Merck & Co. Immuno-oncology Drugs Product and Services
        7.6.4 Merck & Co. Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023)
        7.6.5 Merck & Co. Recent Developments/Updates
        7.6.6 Merck & Co. Competitive Strengths & Weaknesses
    7.7 Hoffmann-La Roche AG
        7.7.1 Hoffmann-La Roche AG Details
        7.7.2 Hoffmann-La Roche AG Major Business
        7.7.3 Hoffmann-La Roche AG Immuno-oncology Drugs Product and Services
        7.7.4 Hoffmann-La Roche AG Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023)
        7.7.5 Hoffmann-La Roche AG Recent Developments/Updates
        7.7.6 Hoffmann-La Roche AG Competitive Strengths & Weaknesses
    7.8 Johnson & Johnson
        7.8.1 Johnson & Johnson Details
        7.8.2 Johnson & Johnson Major Business
        7.8.3 Johnson & Johnson Immuno-oncology Drugs Product and Services
        7.8.4 Johnson & Johnson Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023)
        7.8.5 Johnson & Johnson Recent Developments/Updates
        7.8.6 Johnson & Johnson Competitive Strengths & Weaknesses
    7.9 Novartis International AG
        7.9.1 Novartis International AG Details
        7.9.2 Novartis International AG Major Business
        7.9.3 Novartis International AG Immuno-oncology Drugs Product and Services
        7.9.4 Novartis International AG Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023)
        7.9.5 Novartis International AG Recent Developments/Updates
        7.9.6 Novartis International AG Competitive Strengths & Weaknesses
    7.10 AbbVie, Inc.
        7.10.1 AbbVie, Inc. Details
        7.10.2 AbbVie, Inc. Major Business
        7.10.3 AbbVie, Inc. Immuno-oncology Drugs Product and Services
        7.10.4 AbbVie, Inc. Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023)
        7.10.5 AbbVie, Inc. Recent Developments/Updates
        7.10.6 AbbVie, Inc. Competitive Strengths & Weaknesses
    7.11 Pfizer Inc.
        7.11.1 Pfizer Inc. Details
        7.11.2 Pfizer Inc. Major Business
        7.11.3 Pfizer Inc. Immuno-oncology Drugs Product and Services
        7.11.4 Pfizer Inc. Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023)
        7.11.5 Pfizer Inc. Recent Developments/Updates
        7.11.6 Pfizer Inc. Competitive Strengths & Weaknesses
    7.12 Sanofi S.A.
        7.12.1 Sanofi S.A. Details
        7.12.2 Sanofi S.A. Major Business
        7.12.3 Sanofi S.A. Immuno-oncology Drugs Product and Services
        7.12.4 Sanofi S.A. Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023)
        7.12.5 Sanofi S.A. Recent Developments/Updates
        7.12.6 Sanofi S.A. Competitive Strengths & Weaknesses
    7.13 EMD Serono, Inc.
        7.13.1 EMD Serono, Inc. Details
        7.13.2 EMD Serono, Inc. Major Business
        7.13.3 EMD Serono, Inc. Immuno-oncology Drugs Product and Services
        7.13.4 EMD Serono, Inc. Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023)
        7.13.5 EMD Serono, Inc. Recent Developments/Updates
        7.13.6 EMD Serono, Inc. Competitive Strengths & Weaknesses
    7.14 Gilead Sciences Inc.
        7.14.1 Gilead Sciences Inc. Details
        7.14.2 Gilead Sciences Inc. Major Business
        7.14.3 Gilead Sciences Inc. Immuno-oncology Drugs Product and Services
        7.14.4 Gilead Sciences Inc. Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023)
        7.14.5 Gilead Sciences Inc. Recent Developments/Updates
        7.14.6 Gilead Sciences Inc. Competitive Strengths & Weaknesses
    7.15 Prometheus Therapeutics & Diagnostics
        7.15.1 Prometheus Therapeutics & Diagnostics Details
        7.15.2 Prometheus Therapeutics & Diagnostics Major Business
        7.15.3 Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Product and Services
        7.15.4 Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023)
        7.15.5 Prometheus Therapeutics & Diagnostics Recent Developments/Updates
        7.15.6 Prometheus Therapeutics & Diagnostics Competitive Strengths & Weaknesses
    7.16 Aduro BioTech
        7.16.1 Aduro BioTech Details
        7.16.2 Aduro BioTech Major Business
        7.16.3 Aduro BioTech Immuno-oncology Drugs Product and Services
        7.16.4 Aduro BioTech Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023)
        7.16.5 Aduro BioTech Recent Developments/Updates
        7.16.6 Aduro BioTech Competitive Strengths & Weaknesses
    7.17 Galena Biopharma
        7.17.1 Galena Biopharma Details
        7.17.2 Galena Biopharma Major Business
        7.17.3 Galena Biopharma Immuno-oncology Drugs Product and Services
        7.17.4 Galena Biopharma Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023)
        7.17.5 Galena Biopharma Recent Developments/Updates
        7.17.6 Galena Biopharma Competitive Strengths & Weaknesses
    7.18 Bavarian Nordic
        7.18.1 Bavarian Nordic Details
        7.18.2 Bavarian Nordic Major Business
        7.18.3 Bavarian Nordic Immuno-oncology Drugs Product and Services
        7.18.4 Bavarian Nordic Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023)
        7.18.5 Bavarian Nordic Recent Developments/Updates
        7.18.6 Bavarian Nordic Competitive Strengths & Weaknesses
    7.19 Celldex Therapeutics
        7.19.1 Celldex Therapeutics Details
        7.19.2 Celldex Therapeutics Major Business
        7.19.3 Celldex Therapeutics Immuno-oncology Drugs Product and Services
        7.19.4 Celldex Therapeutics Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023)
        7.19.5 Celldex Therapeutics Recent Developments/Updates
        7.19.6 Celldex Therapeutics Competitive Strengths & Weaknesses
    7.20 ImmunoCellular Therapeutics
        7.20.1 ImmunoCellular Therapeutics Details
        7.20.2 ImmunoCellular Therapeutics Major Business
        7.20.3 ImmunoCellular Therapeutics Immuno-oncology Drugs Product and Services
        7.20.4 ImmunoCellular Therapeutics Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023)
        7.20.5 ImmunoCellular Therapeutics Recent Developments/Updates
        7.20.6 ImmunoCellular Therapeutics Competitive Strengths & Weaknesses
    7.21 Incyte
        7.21.1 Incyte Details
        7.21.2 Incyte Major Business
        7.21.3 Incyte Immuno-oncology Drugs Product and Services
        7.21.4 Incyte Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023)
        7.21.5 Incyte Recent Developments/Updates
        7.21.6 Incyte Competitive Strengths & Weaknesses
    7.22 Dendreon Corporation
        7.22.1 Dendreon Corporation Details
        7.22.2 Dendreon Corporation Major Business
        7.22.3 Dendreon Corporation Immuno-oncology Drugs Product and Services
        7.22.4 Dendreon Corporation Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023)
        7.22.5 Dendreon Corporation Recent Developments/Updates
        7.22.6 Dendreon Corporation Competitive Strengths & Weaknesses
    7.23 Agilent Technologies Inc.
        7.23.1 Agilent Technologies Inc. Details
        7.23.2 Agilent Technologies Inc. Major Business
        7.23.3 Agilent Technologies Inc. Immuno-oncology Drugs Product and Services
        7.23.4 Agilent Technologies Inc. Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023)
        7.23.5 Agilent Technologies Inc. Recent Developments/Updates
        7.23.6 Agilent Technologies Inc. Competitive Strengths & Weaknesses
    7.24 Agenus Inc.
        7.24.1 Agenus Inc. Details
        7.24.2 Agenus Inc. Major Business
        7.24.3 Agenus Inc. Immuno-oncology Drugs Product and Services
        7.24.4 Agenus Inc. Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023)
        7.24.5 Agenus Inc. Recent Developments/Updates
        7.24.6 Agenus Inc. Competitive Strengths & Weaknesses
    7.25 Enzo Biochem, Inc.
        7.25.1 Enzo Biochem, Inc. Details
        7.25.2 Enzo Biochem, Inc. Major Business
        7.25.3 Enzo Biochem, Inc. Immuno-oncology Drugs Product and Services
        7.25.4 Enzo Biochem, Inc. Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023)
        7.25.5 Enzo Biochem, Inc. Recent Developments/Updates
        7.25.6 Enzo Biochem, Inc. Competitive Strengths & Weaknesses
    7.26 Lonza Group
        7.26.1 Lonza Group Details
        7.26.2 Lonza Group Major Business
        7.26.3 Lonza Group Immuno-oncology Drugs Product and Services
        7.26.4 Lonza Group Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023)
        7.26.5 Lonza Group Recent Developments/Updates
        7.26.6 Lonza Group Competitive Strengths & Weaknesses
    7.27 Bio-Rad Laboratories, Inc.
        7.27.1 Bio-Rad Laboratories, Inc. Details
        7.27.2 Bio-Rad Laboratories, Inc. Major Business
        7.27.3 Bio-Rad Laboratories, Inc. Immuno-oncology Drugs Product and Services
        7.27.4 Bio-Rad Laboratories, Inc. Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023)
        7.27.5 Bio-Rad Laboratories, Inc. Recent Developments/Updates
        7.27.6 Bio-Rad Laboratories, Inc. Competitive Strengths & Weaknesses
    7.28 Avantor, Inc.
        7.28.1 Avantor, Inc. Details
        7.28.2 Avantor, Inc. Major Business
        7.28.3 Avantor, Inc. Immuno-oncology Drugs Product and Services
        7.28.4 Avantor, Inc. Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023)
        7.28.5 Avantor, Inc. Recent Developments/Updates
        7.28.6 Avantor, Inc. Competitive Strengths & Weaknesses
    7.29 Spring Bank Pharmaceuticals, Inc.
        7.29.1 Spring Bank Pharmaceuticals, Inc. Details
        7.29.2 Spring Bank Pharmaceuticals, Inc. Major Business
        7.29.3 Spring Bank Pharmaceuticals, Inc. Immuno-oncology Drugs Product and Services
        7.29.4 Spring Bank Pharmaceuticals, Inc. Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023)
        7.29.5 Spring Bank Pharmaceuticals, Inc. Recent Developments/Updates
        7.29.6 Spring Bank Pharmaceuticals, Inc. Competitive Strengths & Weaknesses
    7.30 Ferring Pharmaceuticals
        7.30.1 Ferring Pharmaceuticals Details
        7.30.2 Ferring Pharmaceuticals Major Business
        7.30.3 Ferring Pharmaceuticals Immuno-oncology Drugs Product and Services
        7.30.4 Ferring Pharmaceuticals Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023)
        7.30.5 Ferring Pharmaceuticals Recent Developments/Updates
        7.30.6 Ferring Pharmaceuticals Competitive Strengths & Weaknesses

8 Industry Chain Analysis
    8.1 Immuno-oncology Drugs Industry Chain
    8.2 Immuno-oncology Drugs Upstream Analysis
    8.3 Immuno-oncology Drugs Midstream Analysis
    8.4 Immuno-oncology Drugs Downstream Analysis

9 Research Findings and Conclusion

10 Appendix
    10.1 Methodology
    10.2 Research Process and Data Source
    10.3 Disclaimer

Table of Figures

List of Tables
    Table 1. World Immuno-oncology Drugs Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)
    Table 2. World Immuno-oncology Drugs Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)
    Table 3. World Immuno-oncology Drugs Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)
    Table 4. World Immuno-oncology Drugs Revenue Market Share by Region (2018-2023), (by Headquarter Location)
    Table 5. World Immuno-oncology Drugs Revenue Market Share by Region (2024-2029), (by Headquarter Location)
    Table 6. Major Market Trends
    Table 7. World Immuno-oncology Drugs Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)
    Table 8. World Immuno-oncology Drugs Consumption Value by Region (2018-2023) & (USD Million)
    Table 9. World Immuno-oncology Drugs Consumption Value Forecast by Region (2024-2029) & (USD Million)
    Table 10. World Immuno-oncology Drugs Revenue by Player (2018-2023) & (USD Million)
    Table 11. Revenue Market Share of Key Immuno-oncology Drugs Players in 2022
    Table 12. World Immuno-oncology Drugs Industry Rank of Major Player, Based on Revenue in 2022
    Table 13. Global Immuno-oncology Drugs Company Evaluation Quadrant
    Table 14. Head Office of Key Immuno-oncology Drugs Player
    Table 15. Immuno-oncology Drugs Market: Company Product Type Footprint
    Table 16. Immuno-oncology Drugs Market: Company Product Application Footprint
    Table 17. Immuno-oncology Drugs Mergers & Acquisitions Activity
    Table 18. United States VS China Immuno-oncology Drugs Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)
    Table 19. United States VS China Immuno-oncology Drugs Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)
    Table 20. United States Based Immuno-oncology Drugs Companies, Headquarters (States, Country)
    Table 21. United States Based Companies Immuno-oncology Drugs Revenue, (2018-2023) & (USD Million)
    Table 22. United States Based Companies Immuno-oncology Drugs Revenue Market Share (2018-2023)
    Table 23. China Based Immuno-oncology Drugs Companies, Headquarters (Province, Country)
    Table 24. China Based Companies Immuno-oncology Drugs Revenue, (2018-2023) & (USD Million)
    Table 25. China Based Companies Immuno-oncology Drugs Revenue Market Share (2018-2023)
    Table 26. Rest of World Based Immuno-oncology Drugs Companies, Headquarters (States, Country)
    Table 27. Rest of World Based Companies Immuno-oncology Drugs Revenue, (2018-2023) & (USD Million)
    Table 28. Rest of World Based Companies Immuno-oncology Drugs Revenue Market Share (2018-2023)
    Table 29. World Immuno-oncology Drugs Market Size by Type, (USD Million), 2018 & 2022 & 2029
    Table 30. World Immuno-oncology Drugs Market Size by Type (2018-2023) & (USD Million)
    Table 31. World Immuno-oncology Drugs Market Size by Type (2024-2029) & (USD Million)
    Table 32. World Immuno-oncology Drugs Market Size by Application, (USD Million), 2018 & 2022 & 2029
    Table 33. World Immuno-oncology Drugs Market Size by Application (2018-2023) & (USD Million)
    Table 34. World Immuno-oncology Drugs Market Size by Application (2024-2029) & (USD Million)
    Table 35. Amgen, Inc Basic Information, Area Served and Competitors
    Table 36. Amgen, Inc Major Business
    Table 37. Amgen, Inc Immuno-oncology Drugs Product and Services
    Table 38. Amgen, Inc Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 39. Amgen, Inc Recent Developments/Updates
    Table 40. Amgen, Inc Competitive Strengths & Weaknesses
    Table 41. AstraZeneca, Plc Basic Information, Area Served and Competitors
    Table 42. AstraZeneca, Plc Major Business
    Table 43. AstraZeneca, Plc Immuno-oncology Drugs Product and Services
    Table 44. AstraZeneca, Plc Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 45. AstraZeneca, Plc Recent Developments/Updates
    Table 46. AstraZeneca, Plc Competitive Strengths & Weaknesses
    Table 47. Bristol-Myers Squibb Basic Information, Area Served and Competitors
    Table 48. Bristol-Myers Squibb Major Business
    Table 49. Bristol-Myers Squibb Immuno-oncology Drugs Product and Services
    Table 50. Bristol-Myers Squibb Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 51. Bristol-Myers Squibb Recent Developments/Updates
    Table 52. Bristol-Myers Squibb Competitive Strengths & Weaknesses
    Table 53. Celgene Corporation Basic Information, Area Served and Competitors
    Table 54. Celgene Corporation Major Business
    Table 55. Celgene Corporation Immuno-oncology Drugs Product and Services
    Table 56. Celgene Corporation Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 57. Celgene Corporation Recent Developments/Updates
    Table 58. Celgene Corporation Competitive Strengths & Weaknesses
    Table 59. Eli Lilly and Company Basic Information, Area Served and Competitors
    Table 60. Eli Lilly and Company Major Business
    Table 61. Eli Lilly and Company Immuno-oncology Drugs Product and Services
    Table 62. Eli Lilly and Company Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 63. Eli Lilly and Company Recent Developments/Updates
    Table 64. Eli Lilly and Company Competitive Strengths & Weaknesses
    Table 65. Merck & Co. Basic Information, Area Served and Competitors
    Table 66. Merck & Co. Major Business
    Table 67. Merck & Co. Immuno-oncology Drugs Product and Services
    Table 68. Merck & Co. Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 69. Merck & Co. Recent Developments/Updates
    Table 70. Merck & Co. Competitive Strengths & Weaknesses
    Table 71. Hoffmann-La Roche AG Basic Information, Area Served and Competitors
    Table 72. Hoffmann-La Roche AG Major Business
    Table 73. Hoffmann-La Roche AG Immuno-oncology Drugs Product and Services
    Table 74. Hoffmann-La Roche AG Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 75. Hoffmann-La Roche AG Recent Developments/Updates
    Table 76. Hoffmann-La Roche AG Competitive Strengths & Weaknesses
    Table 77. Johnson & Johnson Basic Information, Area Served and Competitors
    Table 78. Johnson & Johnson Major Business
    Table 79. Johnson & Johnson Immuno-oncology Drugs Product and Services
    Table 80. Johnson & Johnson Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 81. Johnson & Johnson Recent Developments/Updates
    Table 82. Johnson & Johnson Competitive Strengths & Weaknesses
    Table 83. Novartis International AG Basic Information, Area Served and Competitors
    Table 84. Novartis International AG Major Business
    Table 85. Novartis International AG Immuno-oncology Drugs Product and Services
    Table 86. Novartis International AG Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 87. Novartis International AG Recent Developments/Updates
    Table 88. Novartis International AG Competitive Strengths & Weaknesses
    Table 89. AbbVie, Inc. Basic Information, Area Served and Competitors
    Table 90. AbbVie, Inc. Major Business
    Table 91. AbbVie, Inc. Immuno-oncology Drugs Product and Services
    Table 92. AbbVie, Inc. Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 93. AbbVie, Inc. Recent Developments/Updates
    Table 94. AbbVie, Inc. Competitive Strengths & Weaknesses
    Table 95. Pfizer Inc. Basic Information, Area Served and Competitors
    Table 96. Pfizer Inc. Major Business
    Table 97. Pfizer Inc. Immuno-oncology Drugs Product and Services
    Table 98. Pfizer Inc. Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 99. Pfizer Inc. Recent Developments/Updates
    Table 100. Pfizer Inc. Competitive Strengths & Weaknesses
    Table 101. Sanofi S.A. Basic Information, Area Served and Competitors
    Table 102. Sanofi S.A. Major Business
    Table 103. Sanofi S.A. Immuno-oncology Drugs Product and Services
    Table 104. Sanofi S.A. Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 105. Sanofi S.A. Recent Developments/Updates
    Table 106. Sanofi S.A. Competitive Strengths & Weaknesses
    Table 107. EMD Serono, Inc. Basic Information, Area Served and Competitors
    Table 108. EMD Serono, Inc. Major Business
    Table 109. EMD Serono, Inc. Immuno-oncology Drugs Product and Services
    Table 110. EMD Serono, Inc. Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 111. EMD Serono, Inc. Recent Developments/Updates
    Table 112. EMD Serono, Inc. Competitive Strengths & Weaknesses
    Table 113. Gilead Sciences Inc. Basic Information, Area Served and Competitors
    Table 114. Gilead Sciences Inc. Major Business
    Table 115. Gilead Sciences Inc. Immuno-oncology Drugs Product and Services
    Table 116. Gilead Sciences Inc. Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 117. Gilead Sciences Inc. Recent Developments/Updates
    Table 118. Gilead Sciences Inc. Competitive Strengths & Weaknesses
    Table 119. Prometheus Therapeutics & Diagnostics Basic Information, Area Served and Competitors
    Table 120. Prometheus Therapeutics & Diagnostics Major Business
    Table 121. Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Product and Services
    Table 122. Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 123. Prometheus Therapeutics & Diagnostics Recent Developments/Updates
    Table 124. Prometheus Therapeutics & Diagnostics Competitive Strengths & Weaknesses
    Table 125. Aduro BioTech Basic Information, Area Served and Competitors
    Table 126. Aduro BioTech Major Business
    Table 127. Aduro BioTech Immuno-oncology Drugs Product and Services
    Table 128. Aduro BioTech Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 129. Aduro BioTech Recent Developments/Updates
    Table 130. Aduro BioTech Competitive Strengths & Weaknesses
    Table 131. Galena Biopharma Basic Information, Area Served and Competitors
    Table 132. Galena Biopharma Major Business
    Table 133. Galena Biopharma Immuno-oncology Drugs Product and Services
    Table 134. Galena Biopharma Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 135. Galena Biopharma Recent Developments/Updates
    Table 136. Galena Biopharma Competitive Strengths & Weaknesses
    Table 137. Bavarian Nordic Basic Information, Area Served and Competitors
    Table 138. Bavarian Nordic Major Business
    Table 139. Bavarian Nordic Immuno-oncology Drugs Product and Services
    Table 140. Bavarian Nordic Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 141. Bavarian Nordic Recent Developments/Updates
    Table 142. Bavarian Nordic Competitive Strengths & Weaknesses
    Table 143. Celldex Therapeutics Basic Information, Area Served and Competitors
    Table 144. Celldex Therapeutics Major Business
    Table 145. Celldex Therapeutics Immuno-oncology Drugs Product and Services
    Table 146. Celldex Therapeutics Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 147. Celldex Therapeutics Recent Developments/Updates
    Table 148. Celldex Therapeutics Competitive Strengths & Weaknesses
    Table 149. ImmunoCellular Therapeutics Basic Information, Area Served and Competitors
    Table 150. ImmunoCellular Therapeutics Major Business
    Table 151. ImmunoCellular Therapeutics Immuno-oncology Drugs Product and Services
    Table 152. ImmunoCellular Therapeutics Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 153. ImmunoCellular Therapeutics Recent Developments/Updates
    Table 154. ImmunoCellular Therapeutics Competitive Strengths & Weaknesses
    Table 155. Incyte Basic Information, Area Served and Competitors
    Table 156. Incyte Major Business
    Table 157. Incyte Immuno-oncology Drugs Product and Services
    Table 158. Incyte Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 159. Incyte Recent Developments/Updates
    Table 160. Incyte Competitive Strengths & Weaknesses
    Table 161. Dendreon Corporation Basic Information, Area Served and Competitors
    Table 162. Dendreon Corporation Major Business
    Table 163. Dendreon Corporation Immuno-oncology Drugs Product and Services
    Table 164. Dendreon Corporation Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 165. Dendreon Corporation Recent Developments/Updates
    Table 166. Dendreon Corporation Competitive Strengths & Weaknesses
    Table 167. Agilent Technologies Inc. Basic Information, Area Served and Competitors
    Table 168. Agilent Technologies Inc. Major Business
    Table 169. Agilent Technologies Inc. Immuno-oncology Drugs Product and Services
    Table 170. Agilent Technologies Inc. Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 171. Agilent Technologies Inc. Recent Developments/Updates
    Table 172. Agilent Technologies Inc. Competitive Strengths & Weaknesses
    Table 173. Agenus Inc. Basic Information, Area Served and Competitors
    Table 174. Agenus Inc. Major Business
    Table 175. Agenus Inc. Immuno-oncology Drugs Product and Services
    Table 176. Agenus Inc. Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 177. Agenus Inc. Recent Developments/Updates
    Table 178. Agenus Inc. Competitive Strengths & Weaknesses
    Table 179. Enzo Biochem, Inc. Basic Information, Area Served and Competitors
    Table 180. Enzo Biochem, Inc. Major Business
    Table 181. Enzo Biochem, Inc. Immuno-oncology Drugs Product and Services
    Table 182. Enzo Biochem, Inc. Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 183. Enzo Biochem, Inc. Recent Developments/Updates
    Table 184. Enzo Biochem, Inc. Competitive Strengths & Weaknesses
    Table 185. Lonza Group Basic Information, Area Served and Competitors
    Table 186. Lonza Group Major Business
    Table 187. Lonza Group Immuno-oncology Drugs Product and Services
    Table 188. Lonza Group Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 189. Lonza Group Recent Developments/Updates
    Table 190. Lonza Group Competitive Strengths & Weaknesses
    Table 191. Bio-Rad Laboratories, Inc. Basic Information, Area Served and Competitors
    Table 192. Bio-Rad Laboratories, Inc. Major Business
    Table 193. Bio-Rad Laboratories, Inc. Immuno-oncology Drugs Product and Services
    Table 194. Bio-Rad Laboratories, Inc. Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 195. Bio-Rad Laboratories, Inc. Recent Developments/Updates
    Table 196. Bio-Rad Laboratories, Inc. Competitive Strengths & Weaknesses
    Table 197. Avantor, Inc. Basic Information, Area Served and Competitors
    Table 198. Avantor, Inc. Major Business
    Table 199. Avantor, Inc. Immuno-oncology Drugs Product and Services
    Table 200. Avantor, Inc. Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 201. Avantor, Inc. Recent Developments/Updates
    Table 202. Avantor, Inc. Competitive Strengths & Weaknesses
    Table 203. Spring Bank Pharmaceuticals, Inc. Basic Information, Area Served and Competitors
    Table 204. Spring Bank Pharmaceuticals, Inc.Major Business
    Table 205. Spring Bank Pharmaceuticals, Inc. Immuno-oncology Drugs Product and Services
    Table 206. Spring Bank Pharmaceuticals, Inc. Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 207. Spring Bank Pharmaceuticals, Inc. Recent Developments/Updates
    Table 208. Ferring Pharmaceuticals Basic Information, Area Served and Competitors
    Table 209. Ferring Pharmaceuticals Major Business
    Table 210. Ferring Pharmaceuticals Immuno-oncology Drugs Product and Services
    Table 211. Ferring Pharmaceuticals Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 212. Global Key Players of Immuno-oncology Drugs Upstream (Raw Materials)
    Table 213. Immuno-oncology Drugs Typical Customers
List of Figure
    Figure 1. Immuno-oncology Drugs Picture
    Figure 2. World Immuno-oncology Drugs Total Market Size: 2018 & 2022 & 2029, (USD Million)
    Figure 3. World Immuno-oncology Drugs Total Market Size (2018-2029) & (USD Million)
    Figure 4. World Immuno-oncology Drugs Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)
    Figure 5. World Immuno-oncology Drugs Revenue Market Share by Region (2018-2029), (by Headquarter Location)
    Figure 6. United States Based Company Immuno-oncology Drugs Revenue (2018-2029) & (USD Million)
    Figure 7. China Based Company Immuno-oncology Drugs Revenue (2018-2029) & (USD Million)
    Figure 8. Europe Based Company Immuno-oncology Drugs Revenue (2018-2029) & (USD Million)
    Figure 9. Japan Based Company Immuno-oncology Drugs Revenue (2018-2029) & (USD Million)
    Figure 10. South Korea Based Company Immuno-oncology Drugs Revenue (2018-2029) & (USD Million)
    Figure 11. ASEAN Based Company Immuno-oncology Drugs Revenue (2018-2029) & (USD Million)
    Figure 12. India Based Company Immuno-oncology Drugs Revenue (2018-2029) & (USD Million)
    Figure 13. Immuno-oncology Drugs Market Drivers
    Figure 14. Factors Affecting Demand
    Figure 15. World Immuno-oncology Drugs Consumption Value (2018-2029) & (USD Million)
    Figure 16. World Immuno-oncology Drugs Consumption Value Market Share by Region (2018-2029)
    Figure 17. United States Immuno-oncology Drugs Consumption Value (2018-2029) & (USD Million)
    Figure 18. China Immuno-oncology Drugs Consumption Value (2018-2029) & (USD Million)
    Figure 19. Europe Immuno-oncology Drugs Consumption Value (2018-2029) & (USD Million)
    Figure 20. Japan Immuno-oncology Drugs Consumption Value (2018-2029) & (USD Million)
    Figure 21. South Korea Immuno-oncology Drugs Consumption Value (2018-2029) & (USD Million)
    Figure 22. ASEAN Immuno-oncology Drugs Consumption Value (2018-2029) & (USD Million)
    Figure 23. India Immuno-oncology Drugs Consumption Value (2018-2029) & (USD Million)
    Figure 24. Producer Shipments of Immuno-oncology Drugs by Player Revenue ($MM) and Market Share (%): 2022
    Figure 25. Global Four-firm Concentration Ratios (CR4) for Immuno-oncology Drugs Markets in 2022
    Figure 26. Global Four-firm Concentration Ratios (CR8) for Immuno-oncology Drugs Markets in 2022
    Figure 27. United States VS China: Immuno-oncology Drugs Revenue Market Share Comparison (2018 & 2022 & 2029)
    Figure 28. United States VS China: Immuno-oncology Drugs Consumption Value Market Share Comparison (2018 & 2022 & 2029)
    Figure 29. World Immuno-oncology Drugs Market Size by Type, (USD Million), 2018 & 2022 & 2029
    Figure 30. World Immuno-oncology Drugs Market Size Market Share by Type in 2022
    Figure 31. Immune Checkpoint Inhibitors
    Figure 32. Immune System Modulators
    Figure 33. Cancer Vaccines
    Figure 34. Oncolytic Virus
    Figure 35. Others
    Figure 36. World Immuno-oncology Drugs Market Size Market Share by Type (2018-2029)
    Figure 37. World Immuno-oncology Drugs Market Size by Application, (USD Million), 2018 & 2022 & 2029
    Figure 38. World Immuno-oncology Drugs Market Size Market Share by Application in 2022
    Figure 39. Hospitals
    Figure 40. Clinics
    Figure 41. Ambulatory Surgical Centers
    Figure 42. Immuno-oncology Drugs Industrial Chain
    Figure 43. Methodology
    Figure 44. Research Process and Data Source

Companies Mentioned

Amgen, Inc
AstraZeneca, Plc
Bristol-Myers Squibb
Celgene Corporation
Eli Lilly and Company
Merck & Co.
Hoffmann-La Roche AG
Johnson & Johnson
Novartis International AG
AbbVie, Inc.
Pfizer Inc.
Sanofi S.A.
EMD Serono, Inc.
Gilead Sciences Inc.
Prometheus Therapeutics & Diagnostics
Aduro BioTech
Galena Biopharma
Bavarian Nordic
Celldex Therapeutics
ImmunoCellular Therapeutics
Incyte
Dendreon Corporation
Agilent Technologies Inc.
Agenus Inc.
Enzo Biochem, Inc.
Lonza Group
Bio-Rad Laboratories, Inc.
Avantor, Inc.
Spring Bank Pharmaceuticals, Inc.
Ferring Pharmaceuticals